BMY News and Press, Bristol-Myers Squibb Company From 05/02/24

2024-05-02 07:00:00 ET Summary Value investors have been frustrated as growth stocks have outperformed for the past 15 years. Value investing is a long-term strategy that requires patience and a focus on fundamentals. Three blue-chip stocks, Bristol-Myers, Zoetis, and Monster ...

2024-05-01 12:12:21 ET More on Editas Medicine Editas Medicine, Inc. (EDIT) Presents at Barclays 26th Annual Global Healthcare Conference (Transcript) Editas Medicine, Inc. (EDIT) Leerink Partners Global Biopharma Conference (Transcript) Editas Medicine, Inc. (EDIT) ...

2024-05-01 09:00:00 ET Summary April 2024 jobs report expected to show an increase of 250,000 jobs, indicating continued tightness in the labor market. Healthcare sector likely to add jobs, while drug manufacturers may struggle. Construction, government, energy, and beverage i...

2024-05-01 08:37:31 ET More on Pfizer Is 7%-Yielding Pfizer Stock A Buy On The Dip Before Q1? Unveiling Pfizer's Potent Cocktail: Key Drivers Of Free Cash Flow Growth Pfizer's Doldrums, Just A Bad Case Of COVID-19? Pfizer beats top-line and bottom-line estima...

CAMBRIDGE, Mass., May 01, 2024 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a clinical-stage gene editing company, today announced a two-year extension to the collaboration with Bristol Myers Squibb (NYSE: BMY) under which the parties may research, develop, and commercialize autologo...

2024-04-30 13:10:58 ET More on Contineum Therapeutics, Inc. Contineum Therapeutics Seeks $150 Million IPO For MS Treatments Contineum Therapeutics stock slides 10% following $110M IPO Contineum Therapeutics prices initial offering at $16 per share Financial i...

2024-04-30 09:49:06 ET More on Bristol-Myers, Johnson & Johnson, etc. Bristol Myers Squibb: Tough Times Continue Bristol-Myers Squibb Company (BMY) Q1 2024 Earnings Call Transcript Bristol-Myers Squibb Stock: Gloomy Q1 Earnings Trigger Justified Sell-Off ...

2024-04-30 05:29:18 ET Summary Bristol Myers Squibb faces challenges due to the loss of exclusivity of its top-selling drug Revlimid, upcoming loss of exclusivity, and a large net debt load. The company made several acquisitions to offset pipeline flaws, but its midterm outlook is...

2024-04-29 15:08:53 ET Summary AbbVie Inc.'s shares dropped last week due to concerns about the erosion of Humira and despite the company beating revenue and EPS expectations. Humira's global sales fell 36% YoY, but AbbVie's other growth products performed well, leading to overall...

2024-04-29 09:06:36 ET Bristol-Myers Squibb Company (BMY) Q1 2024 Earnings Conference Call April 25, 2024, 8:00 AM ET Company Participants Tim Power - Vice President, Investor Relations Chris Boerner - Board Chair and Chief Executive Officer David Elkins - Execut...